Last reviewed · How we verify
TTAC-0001 and pembrolizumab combination — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TTAC-0001 and pembrolizumab combination (TTAC-0001 and pembrolizumab combination) — PharmAbcine.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TTAC-0001 and pembrolizumab combination TARGET | TTAC-0001 and pembrolizumab combination | PharmAbcine | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TTAC-0001 and pembrolizumab combination CI watch — RSS
- TTAC-0001 and pembrolizumab combination CI watch — Atom
- TTAC-0001 and pembrolizumab combination CI watch — JSON
- TTAC-0001 and pembrolizumab combination alone — RSS
Cite this brief
Drug Landscape (2026). TTAC-0001 and pembrolizumab combination — Competitive Intelligence Brief. https://druglandscape.com/ci/ttac-0001-and-pembrolizumab-combination. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab